| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2009PNAS..106.7137C |
| P356 | DOI | 10.1073/PNAS.0812317106 |
| P932 | PMC publication ID | 2678451 |
| P698 | PubMed publication ID | 19359485 |
| P5875 | ResearchGate publication ID | 24271069 |
| P50 | author | Arturo Brunetti | Q45394961 |
| Valeria Tarallo | Q56982769 | ||
| Adelaide Greco | Q57613439 | ||
| Miho Nozaki | Q74198127 | ||
| P2093 | author name string | Balamurali K Ambati | |
| Mark E Kleinman | |||
| Jayakrishna Ambati | |||
| Judit Z Baffi | |||
| Romulo J C Albuquerque | |||
| Won Gil Cho | |||
| Jonathan S Alexander | |||
| Sandro De Falco | |||
| Massimo De Falco | |||
| Martha G Green | |||
| P2860 | cites work | Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7 | Q24295641 |
| Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA | Q27650381 | ||
| Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 | Q27860854 | ||
| Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif | Q28629445 | ||
| Angiogenesis in life, disease and medicine | Q29614539 | ||
| Expression profiling reveals off-target gene regulation by RNAi | Q29615965 | ||
| Angiogenesis as a therapeutic target | Q29619525 | ||
| Activation of the interferon system by short-interfering RNAs | Q29620341 | ||
| Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways | Q33197029 | ||
| The molecular structure of the Toll-like receptor 3 ligand-binding domain. | Q33911664 | ||
| Crystal structure of human toll-like receptor 3 (TLR3) ectodomain | Q33987865 | ||
| Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling | Q34361655 | ||
| Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 | Q34764750 | ||
| The TLR3 signaling complex forms by cooperative receptor dimerization | Q36423463 | ||
| Targeting VEGF-A to treat cancer and age-related macular degeneration | Q36628552 | ||
| Interfering with disease: a progress report on siRNA-based therapeutics | Q36836598 | ||
| The endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing | Q37317551 | ||
| Waterborne infectious diseases--could they be consigned to history? | Q39002261 | ||
| Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation | Q39949251 | ||
| Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery | Q39968577 | ||
| Human lymphatic endothelial cells express multiple functional TLRs. | Q40010175 | ||
| Expression of IL-12-related molecules in human intestinal microvascular endothelial cells is regulated by TLR3. | Q40065672 | ||
| Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA. | Q40091283 | ||
| C-terminal LRRs of human Toll-like receptor 3 control receptor dimerization and signal transmission | Q40128835 | ||
| TLR3 can directly trigger apoptosis in human cancer cells. | Q40296182 | ||
| Isolation and characterization of a novel mouse lymphatic endothelial cell line: SV-LEC. | Q40367765 | ||
| Double-stranded RNA signaling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain | Q40679850 | ||
| Toll-like receptor 3 and geographic atrophy in age-related macular degeneration | Q41888443 | ||
| Interferon induction and its dependence on the primary and secondary structure of poly(inosinic acid).poly(cytidylic acid) | Q43658445 | ||
| Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. | Q44043660 | ||
| Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs | Q45147309 | ||
| Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. | Q51794680 | ||
| Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain. turtle nija occasionally | Q53581243 | ||
| Visualizing a Correlation between siRNA Localization, Cellular Uptake, and RNAi in Living Cells | Q57360062 | ||
| Ocular Neovascularization | Q60060646 | ||
| Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems | Q60169449 | ||
| A second binding site for double-stranded RNA in TLR3 and consequences for interferon activation | Q60214093 | ||
| Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA | Q81547115 | ||
| Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors | Q81772313 | ||
| Plgf-/-eNos-/- mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia | Q83142912 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| P304 | page(s) | 7137-7142 | |
| P577 | publication date | 2009-04-09 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth | |
| P478 | volume | 106 |
| Q40104423 | A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry |
| Q30519445 | A TRIF-independent branch of TLR3 signaling |
| Q38250103 | A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. |
| Q37969941 | A window to innate neuroimmunity: Toll-like receptor-mediated cell responses in the retina |
| Q38351487 | Advances, nuances, and potential pitfalls when exploiting the therapeutic potential of RNA interference. |
| Q34824054 | Age-related macular degeneration and the other double helix. The Cogan Lecture |
| Q36867137 | Bevasiranib for the treatment of wet, age-related macular degeneration |
| Q41370209 | Blocking neuropilin-2 enhances corneal allograft survival by selectively inhibiting lymphangiogenesis on vascularized beds. |
| Q38162098 | Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology |
| Q84878083 | Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery |
| Q38383297 | Clinical translation of RNAi-based treatments for respiratory diseases |
| Q38221915 | Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge. |
| Q36071638 | Current progress of siRNA/shRNA therapeutics in clinical trials |
| Q28235733 | Current prospects for RNA interference-based therapies |
| Q37936378 | Delivery of RNAi mediators |
| Q36174842 | Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering |
| Q35975699 | Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro |
| Q37665372 | Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook |
| Q26752799 | From selection hits to clinical leads: progress in aptamer discovery |
| Q97567741 | Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update |
| Q47578379 | Grand challenges in modulating the immune response with RNAi nanomedicines. |
| Q37010132 | Hemangiogenesis and lymphangiogenesis in corneal pathology |
| Q27691454 | Horizons in therapy for corneal angiogenesis |
| Q60647750 | Human IgG1 antibodies suppress angiogenesis in a target-independent manner |
| Q63915438 | IRF3 and IRF7 mediate neovascularization via inflammatory cytokines. |
| Q36044790 | In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important |
| Q36996592 | Induced pluripotent stem cells in cardiovascular drug discovery |
| Q41695212 | Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin |
| Q60647752 | Intravenous immune globulin suppresses angiogenesis in mice and humans |
| Q34102905 | Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition |
| Q41917981 | Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model |
| Q38106032 | Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. |
| Q36696450 | Nanotechnology in corneal neovascularization therapy--a review |
| Q33710058 | Non-viral siRNA delivery into the mouse retina in vivo |
| Q37681157 | Novel aspects of corneal angiogenic and lymphangiogenic privilege. |
| Q47797906 | Periostin in vitreoretinal diseases. |
| Q40516283 | Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response. |
| Q35090497 | Protein kinase Cα downregulation via siRNA-PKCα released from foldable capsular vitreous body in cultured human retinal pigment epithelium cells |
| Q37979387 | RNA-based therapeutics: current progress and future prospects. |
| Q34527525 | Repeatability, reproducibility and standardisation of a laser Doppler imaging technique for the evaluation of normal mouse hindlimb perfusion. |
| Q35783804 | Resistance to HSV-1 infection in the epithelium resides with the novel innate sensor, IFI-16 |
| Q37200838 | Retinal angiogenesis suppression through small molecule activation of p53 |
| Q37055774 | Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress |
| Q35665149 | Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. |
| Q34358256 | Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma |
| Q38128390 | Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy |
| Q37809577 | Staying on message: design principles for controlling nonspecific responses to siRNA. |
| Q55387361 | Stimulation of TLR3 triggers release of lysosomal ATP in astrocytes and epithelial cells that requires TRPML1 channels. |
| Q38382964 | The application of RNAi-based treatments for inflammatory bowel disease |
| Q37554382 | The future of uveitis treatment |
| Q41819513 | Therapeutic Effect of Novel Single-Stranded RNAi Agent Targeting Periostin in Eyes with Retinal Neovascularization |
| Q96609193 | Therapeutic siRNA: state of the art |
| Q27316003 | Toll like receptor 3 plays a critical role in the progression and severity of acetaminophen-induced hepatotoxicity |
| Q39409767 | Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). |
| Q50237265 | Toll-like receptor 3 activation in retinal pigment epithelium cells - Mitogen-activated protein kinase pathways of cell death and vascular endothelial growth factor secretion. |
| Q91868646 | Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation |
| Q30432794 | Toll-like receptor 3 ligand dampens liver inflammation by stimulating Valpha 14 invariant natural killer T cells to negatively regulate gammadeltaT cells |
| Q40202451 | Toll-like receptor 3 signalling mediates angiogenic response upon shock wave treatment of ischaemic muscle. |
| Q54500544 | poly(I:C) costimulation induces a stronger antiviral chemokine and granzyme B release in human CD4 T cells than CD28 costimulation. |
| Q38043064 | siRNA delivery: from lipids to cell-penetrating peptides and their mimics |
Search more.